INTRODUCTION
Managing populations of commensal rodents is essential. By sharing our environment, they can transmit to humans, directly or indirectly, more than 40 zoonotic pathogens, such as Yersinia pestis, Hantavirus, and Leptospirosis sp. (Buckle and Smith 2015) . They can cause the destruction or degradation of cereals, accounting for nearly 10% of the grain crops in the world, with considerable variation depending on the country (Buckle and Smith 2015) (Battersby 2004) . Rodents also damage substructures and electronic networks.
The management of rodent populations should be based on sanitary and architectural approaches. However, these approaches are often widely associated with the use of rodenticides. The sophisticated social organization of the populations of rats and neophobic behavior of these animals make the action of toxicity with an immediate effect completely ineffective. The only really effective molecules that can be used to manage such populations are anticoagulant rodenticides (ARs). Their delayed action, with mortality occurring several days after consumption, makes them effective in controlling neophobic species. Indeed, ARs, by inhibiting the VKORC1-dependent vitamin K epoxide reductase activity, lead to the progressive reduction of the pool of vitamin K necessary for the activation of clotting factors II, VII, IX, and X (Suttie 1985; Furie and Furie 1988) . Therefore, prolonged or repeated exposure to ARs leads to rodent death by hemorrhage within 3 to 7 days. ARs are usually classified into two generations. The first generation of ARs includes diphacinone, warfarin, coumatetralyl, and chlorophacinone. The second generation of ARs includes bromadiolone, difenacoum, brodifacoum, flocoumafen, and difethialone. All ARs are 4-hydroxycoumarin derivatives except chlorophacinone and diphacinone, which is a derivative of indane-1,3-dione (Hadler and Buckle 1992) . 6 first case of resistance to FGARs in brown rats was observed in 1958 in the United Kingdom (Boyle 1960) . In the following years, resistance was reported everywhere in rats and mice in Europe (Dodsworth 1961) , the United States (Jackson and Kaukeinen 1972) , Canada (Siddiq and Blaine 1982) , Australia (Saunders 1978) , and Japan. The most common resistance mechanism is a result of single-nucleotide polymorphisms (SNPs) in the Vkorc1 gene, leading to an enzyme that is less sensitive to the action of ARs (Li et al. 2004; Rost et al. 2004 ).
The development of second-generation ARs (SGARs) resulted from the emergence of resistance to FGARs in rodent populations. SGARs have been registered from 1975 to 1984, with difenacoum being used first, followed by brodifacoum, bromadiolone, difethialone, and flocoumafen. They are more potent and active after only one feeding due to their longer halflife (Vandenbroucke et al. 2008 ). Nevertheless, due to their increased tissue persistency, nontarget poisoning by SGARs is commonly described in wildlife. Different species are affected by this exposition, such as stoats, weasels (Elmeros et al. 2011) , red foxes (Sage et al. 2010; Geduhn et al. 2015) , European minks (Fournier-Chambrillon et al. 2004) , bobcats (Serieys et al. 2015) , various raptors such as red kite, buzzards, kestrels, peregrine falcons and eagle owls (Thomas et al. 2011; Christensen et al. 2012; Hughes et al. 2013; Langford et al. 2013; RuizSuárez et al. 2014) . ARs were thus identified by the European Union as candidates for future comparative risk assessment and substitution. However, in the absence of an alternative, AR molecules were included in Annex 1 of the EU Biocidal Products Directive 98/8/EC, and their use is still tolerated until a more appropriate solution is found.
This study proposes a method of developing a new generation of ARs by improving the old SGARs based on the concept of stereochemistry. A previous study (Damin-Pernik et al. 2016) demonstrated that difenacoum, the first developed SGAR, is a mixture of two diastereomeric forms, namely, 43% of the composition is trans-isomers, with a short half-life and 57% of the composition is cis-isomers, with a long half-life. The production of a new difenacoum This article has not been copyedited and formatted. The final version may differ from this version. (Kelly et al. 1993; Buckle and Smith 2015) . Therefore, all SGARs are a mixture of two diastereomeric forms that could have different biological properties. This study aimed to explore the differences in the biological properties of the diastereomers of SGARs and to propose the best diastereomer of each SGAR mixture to use as a rodenticide.
This article has not been copyedited and formatted. The final version may differ from this version. Parliament, 2007 Parliament, , 2009 ) and patents (Caruel et al, 2015 (Tishler et al. 1940) . Purity was estimated by LC/MS and was higher than 99%. High-performance liquid chromatography (HPLC)-grade water, which was prepared using a milli-Q plus system (Millipore, Saint-Quentin en Yvelines, France), was used for the preparation of the HPLC eluents.
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Pharmacokinetic study
Male OFA Sprague-Dawley rats received, by per os administration, cis-or trans-isomers of difenacoum, bromadiolone, flocoumafen, brodifacoum, and difethialone. Anticoagulants were dissolved in 10% DMSO and 90% vegetable oil and were administered by force feeding. The animals were given a daily subcutaneous injection of vitamin K1 (5 mg/kg). Finally, the rats were anesthetized with Vetflurane ® . Blood samples were obtained via terminal blood collection by cardiac puncture in citrated tubes. The rats were euthanized with CO 2 , and the livers were then collected and stored at -20°C until analysis.
No-choice feeding test with cis-or trans-isomers of bromadiolone and difethialone
Before testing, all of the animals were maintained on diet A04 (Scientific Animal Food and Engineering) and water ad libitum. Individuals were weighed before the start of the test. Nochoice feeding tests were performed on groups of 10 rats. The rats were fed bait containing 0.005% cis-or trans-isomers of bromadiolone or 0.0015% cis-or trans-isomers of difethialone. Cis-and trans-isomers of bromadiolone and of difethialone are pure at 93, 98, This article has not been copyedited and formatted. The final version may differ from this version. 10 99, and 94%, respectively (the remaining part is the other stereoisomer). Feeding periods of 4 days were used. The contents of food pots were weighed daily, and the intake of bait was recorded. The mortality of rats was also observed daily. At the end of the feeding period with toxic baits, the animals were given diet A04 again and were observed for an additional period of 17 days.
Determination of AR concentration in the liver
Liver tissue (1 g) was extracted with acetone using an Ultra Turrax tissue disperser from IKA under a gentle nitrogen flow. Dry extract was resuspended in acetonitrile/hexane (50%/50%).
The hexane layer was eliminated, and the remainder was dried at 60°C under a gentle nitrogen flow. The final dry extract was dissolved in methanol, and the AR concentrations were analyzed by HPLC on a reverse phase C-18 column (4.6×150 mm, 5 μ m; Waters, Milford, MA, USA) at detection wavelengths of 258, 260, 265, 267, and 272 nM for difenacoum, difethialone, bromadiolone, brodifacoum, and flocoumafen, respectively. The C-18 column was heated at 40°C for difenacoum, bromadiolone, flocoumafen, and brodifacoum and at 30°C for difethialone. A gradient elution system was used with a flow rate of 1 mL/min as follows: from 30% methanol/70% water (acidified with 0.2% H 3 PO 4 ) to 70% methanol/30%
water at 10 min for difenacoum; from 30% acetonitrile/70% water (acidified with 0.1% H 3 PO 4 ) to 90 acetonitrile/10% water at 14 min for brodifacoum; from 60% methanol/40%
water (acidified with 0.2% H 3 PO 4 ) to 80% methanol/20% water at 20 min for bromadiolone; from 60% methanol/40% water (acidified with 0.2% H 3 PO 4 ) to 90% methanol/10% water at This article has not been copyedited and formatted. The final version may differ from this version. to 75% acetonitrile/25% water at 10 min for difethialone. The recovery rate of diastereomers of SGAR from tissues were between 75 to 95 % in liver and the CV% values for precision of the different ARs were less than 15%.
VKOR activity assay and kinetics
Liver microsomes were prepared from fresh livers by differential centrifugation according to the protocol described by Hodroge et al. (2011) . Microsomal vitamin K epoxide reductase (VKOR) activity was assayed according to the protocol described by Hodroge et al. (2011 Hodroge et al. ( , 2012 . The inhibiting effect of the silica gel column-purified cis-or trans-isomers of ARs was evaluated by the determination of Ki after the addition of various concentrations of the anticoagulant to the standard reaction in the presence of increasing amounts of vitamin K epoxide (from 0.001 to 0.2 mM) using anticoagulant concentrations from approximately 0.05 to 20 × Ki.
Data analysis
Pharmacokinetic calculations were performed using the noncompartmental approach on the mean results per group. The elimination half-life (t 1/2(el) ) was calculated using linear regression in GraphPad Prism 6 software (California, USA). The total area under the curve (AUC) was calculated using the linear trapezoidal method and adding the estimated terminal portion of the curve (AUC 0→∞). Statistical analysis of pharmacokinetic parameters were done using GraphPad Prism 6 software (CA, USA 
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RESULTS
Separation of the diastereoisomers of SGARs
The analysis of SGARs by HPLC on a C18 reverse phase column as described in the experimental procedure showed, for each compound, two different peaks corresponding to the cis-and trans-diastereomer forms. The structures of the cis-and trans-isomers of flocoumafen, difethialone, brodifacoum, bromadiolone, and difenacoum are shown in Figs 
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The profile of elimination was the same for the 5 molecules studied; specifically, one isomer was eliminated more quickly than the other, and the decrease followed a clear biphasic profile. For difenacoum, difethialone, and brodifacoum, the cis-isomer was eliminated less rapidly than the trans-isomer. However, for bromadiolone and flocoumafen, the cis-isomer is eliminated more quickly. The half-lives and areas under the curve (AUCs) of the trans-and cis-isomers in the liver were calculated using a linear regression model and are presented in Table 1 .
Analysis of the inhibiting effect of the trans-and cis-isomers of SGARs on vitamin K epoxide reductase activity
The ability of the cis-and trans-isomers of each SGAR to inhibit the VKOR activity catalyzed by warfarin-susceptible rat liver microsomes was evaluated by determining Ki constants. The results are presented in Table 2 . The cis-and trans-isomers of each SGAR were all able to inhibit VKOR activity. For each SGAR, the Ki constants were similar between the diastereomers.
No-choice feeding test with the cis-or trans-isomers of bromadiolone or difethialone
A no-choice feeding test was performed to confirm the efficiency of baits enriched with the less persistent pair of diastereomers and to determine the benefits in term of liver residues.
Assays were performed with bait containing mainly one isomer of bromadiolone or difethialone at the concentrations of 50 and 15 ppm for bromadiolone and difethialone, respectively (Table 3) . Bromadiolone was chosen because it is the SGAR with the greatest difference of half-life between cis-and trans-isomers. Difethialone was chosen because it is the SGAR with the smallest difference of half-life between cis-and trans-isomers. The baits were composed of 93% cis-isomers with 7% trans-isomers or 2% cis-isomers with 98% transisomers for bromadiolone and 6% cis-isomers with 94% trans-isomers or 99% cis-isomers This article has not been copyedited and formatted. The final version may differ from this version. 15 with 1% trans-isomers for difethialone. The daily consumption of baits was similar for the first 3 days between treatments, with an important decrease on day four. A 100% mortality rate was observed for all of the baits used. Regardless of the bait used, the rats died in an average of 5 days, with mortality observed between days 3 and 9. The concentrations of the AR residues were determined after the death of the rats. The residues of bromadiolone in the liver following the death of the rats were 4-fold reduced using the bait containing principally the cis-isomers compared with the bait containing the trans-isomers of bromadiolone. The residues of difethialone in the liver were only 1.5-fold reduced using the trans-isomers compared with the cis-isomers.
This article has not been copyedited and formatted. The final version may differ from this version. (Hunter et al. 1988; Huckle et al. 1988; Kelly et al. 1993; European Parliament 2007; Cort et al. 2012) , which are generally easy to separate and purify.
To rapidly generate the TGARs, it is necessary to revisit the SGARs to identify the diastereomer of each SGAR with the smallest half-life and increase its amount in each mixture.
The data found in the scientific literature, in the regulatory documents, allowed the systematic identification of the major and minor diastereomers in the commercial preparation of each SGAR. Flocoumafen, difenacoum, and brodifacoum are a mixture of 50 to 80% cis-isomers and 20 to 50% trans-isomers (Swaine 1985; Kelly et al. 1993; European Parliament 2009; Damin-Pernik et al. 2016) ; bromadiolone is a mixture of more than 70 of trans-isomers and less than 30% of cis-isomers; and difethialone is a mixture of more than 70 of cis-isomers and 17 less than 30% of trans-isomers (Caruel et al. 2015) . The original reasons for the development of SGARs with such ratios between diastereomers have never been mentioned previously in the literature. We could assume that such ratios resulted from the need to kill the rodent after a single administration when these SGAR were developed (Hadler and Buckle 1992) by enriching the mix with either the most potent inhibitor or the most persistent pair of diastereomer. Another possibility is that the SGAR synthesis process does not give a racemate but a mixture of isomers enriched in one of them.
To characterize the inhibiting properties, ability to inhibit VKOR activity of cis-or transisomers of SGAR was determined. Ki results obtained in this study demonstrated that cis-and trans-isomers of the same SGAR could similarly inhibit VKOR activity (Table 2 and Fig. 6 ).
Therefore, at identical hepatic concentrations, diastereomers of the same SGAR have the same anticoagulant properties when used in warfarin-susceptible rats.
To characterize the tissue persistence, toxicokinetic analyses were done. These toxicokinetic studies were conducted in rats after a single oral administration of the AR. This administration was performed by force feeding to better control the dose and time of ingestion. The same dose was used between SGARs regardless of the LD50 to be able to compare the molecules.
Only the concentrations of ARs in the liver could be followed for 21 days because plasma and other tissue concentrations rapidly decrease below the LOQ. Two toxicokinetic parameters were calculated in this study, the AUC and half-life (Table 1 and 18 for the minor diastereoisomer, except for flocoumafen, for which the lowest AUC was observed for the major diastereomer of the current commercial preparation. Because AUCs could be affected by absorption or clearance, the half-life of diastereomers in the liver was also calculated. Interestingly, the diastereomer with the lowest AUC systematically corresponded to the diastereomer with the lowest half-life in the liver, suggesting a faster elimination of this diastereomer than of the other one. This result was already demonstrated for difenacoum (Damin-Pernik et al. 2016 ).
These AUC and half-life differences between diastereomers of the same SGAR could result in major practical consequences. The composition of each SGAR could thus be systematically modified to enrich the mixture with the less persistent diastereomer to obtain a new AR with the same anticoagulant properties but with decreased tissue persistence. Thus, a new bromadiolone containing more than 70% cis-isomers and a new brodifacoum, difenacoum, or difethialone containing more than 70% trans-isomers may be developed to create the new generation of anticoagulants.
The benefits will be greater for the current ARs i) containing essentially the most persistent diastereomer and ii) with the most significant differences in half-life between the diastereoisomers. Bromadiolone and difethialone were chosen because bromadiolone is the most favorable example to illustrate the concept (highest difference in AUC and half-life and high percentage of the persistent diastereomer in the current mixture), while difethialone is the most unfavorable example (almost no difference in the AUC between the diastereomers).
To illustrate this benefit, the efficiency and persistence of 4 different types of baits were evaluated: a bait containing the current bromadiolone mixture was compared with a bait containing a new bromadiolone mixture containing 93% cis-isomers, and a bait containing the current difethialone mixture was compared with a bait containing a new difethialone mixture containing 94% trans-isomers. The baits were all effective, with 100% mortality obtained 19 after 4 days of exposure at the current commercial concentration for bromadiolone baits or even below for difethialone baits (concentrations of commercial baits containing bromadiolone or difethialone is currently 50 ppm and 25 ppm, respectively). However, the baits enriched with the lowest persistent diastereomer systematically showed a decrease in the quantity of residues in the liver at the time of death of the animals. The reduction of the residues in the liver was greater for bromadiolone enriched in cis-isomers with a 4-fold reduction of the residues compared with the current bromadiolone. For difethialone, the use of trans-isomers reduced the liver residues by a factor of approximately 2 compared with the current difethialone.
The development of such baits enriched in the less persistent diastereomer could avoid the ecotoxicological risk associated with their use, especially regarding plant protection. These baits would reduce the amount of residues at the time of death of the rodents. Nevertheless, if these dying rodents with reduced residues are eaten by scavengers or predators, the elimination of such an AR could also be accelerated in the liver of scavengers or predators.
Therefore, the ecotoxicological gain could be at both levels, and these TGARs would be a good solution to avoid environmental problems associated with pest management.
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